Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290 is registered in ClinicalTrials.gov with TearClear Corp as lead sponsor.

NCT NCT05165290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05165290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure
Lead sponsor
TearClear Corp
Phase
Phase 3
Overall status
Unknown status
Start date
November 29, 2021
Completion date
September 30, 2022
Enrollment
300 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

elevated intraocular pressure